To develop nonprostanoid prostacyclin receptor agonists with a high degree of metabolic resistance and an extended duration of action, a novel series of diphenylpyrazine derivatives was synthesized and evaluated for their inhibition of ADP-induced human platelet aggregation. Structure–activity relationship studies on the side chain containing the carboxylic acid moiety of the lead compound 5c showed that the length of the linker and ...
![2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butyl ester Structure](https://image.chemsrc.com/caspic/404/475084-96-9.png)
